HCA Stock HCA Healthcare (HCA, $328.46) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 17, 2025

GET DAILY SIGNALS

Get AI intraday signals

HCA - HCA Healthcare

MACD signal

View

Odds of UP Trend

Price: $328.46

Daily change: +$9.79 (+3.07%)

Daily volume: 1.1M

Capitalization: $78.6B

Industry: Medical/Nursing Services

Momentum Indicator for HCA turns positive, indicating new upward trend

HCA saw its Momentum Indicator move above the 0 level on March 25, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned positive. In of the 85 cases, the stock moved higher in the following days. The odds of a move higher are at .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for HCA just turned positive on March 17, 2025. Looking at past instances where HCA's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

HCA moved above its 50-day moving average on March 14, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HCA advanced for three days, in of 334 cases, the price rose further within the following month. The odds of a continued upward trend are .

HCA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 364 cases where HCA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (4.616). P/E Ratio (17.402) is within average values for comparable stocks, (71.885). Projected Growth (PEG Ratio) (1.474) is also within normal values, averaging (1.595). Dividend Yield (0.007) settles around the average of (0.026) among similar stocks. P/S Ratio (1.404) is also within normal values, averaging (9.164).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HCA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.